Scala Biodesign

📍 Tel Aviv, Israel🗓 Founded 2022👥 33 employees💰 Last funded Jul 2026
Software Development🌐 scala-bio.com
Website LinkedIn
Scala Biodesign stands at the forefront of the current revolution in protein design. Scala’s no-code one-shot software enables R&D teams to design their proteins in a single design cycle, increasing success rates, reducing R&D effort, and accelerating time-to-market. Scalas technologies, developed by its founding team at the Weizmann Institute of Science, are backed by an unprecedented record of over 130 peer-reviewed publications and collaborations with 80 commercial and academic partners. This includes the first-ever one-shot design of a malaria vaccine candidate, now advancing through Phase II clinical trials, and proteins that were previously considered out of reach across biotherapeutics, enzymes for biomanufacturing, diagnostics, and other bio-based products. Utilizing this unique edge, Scala aims to disrupt the field and democratize the way proteins are developed. Scala has already partnered with five of the top-20 pharmaceutical companies and other market leaders across multiple verticals.
3
Total investors
0
Early stage
3
Mid stage
0
Late stage
2022
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Israel
3
Investor activity2025–2026 · investors recorded per year
2025120262
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Scala Biodesign?
Scala Biodesign has 3 investors on record on gritt.io, 3 mid-stage.
When did Scala Biodesign last raise funding?
The most recent investment in Scala Biodesign recorded on gritt.io was in July 2026.
When was Scala Biodesign founded?
Scala Biodesign was founded in 2022.
What industry is Scala Biodesign in?
Scala Biodesign operates in Software Development. Find similar Software Development investors on gritt.io.
Where is Scala Biodesign based?
Scala Biodesign is headquartered in Tel Aviv, Israel.